Mirdametinib treatment
US11839595B2 · kind B2 · utility
2Cited by
2References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2023 |
| Grant date | Dec 12, 2023 |
| Priority date | — |
| Expiry date | Mar 20, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.